15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Q32 Bio Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $13.00 to $66.00 (about 5.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $33.25 sits 120% above the current $15.14. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.38 next quarter toward $-1.42 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Q32 Bio Inc.
As of Jul, 5 of 5 firms rate QTTB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
QTTB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.50 – $-0.20 · 5 analysts · -36% YoY
Next period, 5 analysts expect Q32 Bio Inc to earn $-0.38 a share (range $-0.50 – $-0.20), versus $-0.60 a year earlier. Full-year consensus is $-1.46, growing to $-1.42 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $1.0M, rising to $1.0M next year.
Top analysts covering Q32 Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on QTTB.
#1
Yatin Suneja
Guggenheim · Rank #28
Hold
No targeton QTTB
Overall win rate
52%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$13.00-14.1% to target
Overall win rate
32%
+ Follow
#3
Jay Olson
Oppenheimer · Rank #302
Buy
$40.00+164.2% to target
Overall win rate
32%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #350
Buy
$66.00+335.9% to target
Overall win rate
32%
+ Follow
#5
ED
Etzer Darout
BMO Capital
Hold
$3.00-80.2% to target
Coverage
—
+ Follow
QTTB stock forecast FAQ
What is QTTB's average 12-month price target?+
The 4 analysts with a live target average $33.25 for Q32 Bio Inc over the next 12 months, ranging from a $66.00 high to a $13.00 low.
Is QTTB stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for QTTB?+
The Street-high target is $66.00 (Wells Fargo), and the Street-low is $13.00 (HC Wainwright & Co.). The average of all 4 active targets is $33.25.
How many Wall Street analysts cover QTTB?+
5 analysts have an active rating on Q32 Bio Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering QTTB?+
Among analysts who currently cover QTTB, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Hold.
What is Q32 Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.50 – $-0.20) across 5 analysts. Full-year EPS is projected at $-1.46, rising to $-1.42 the following year.
How much revenue is Q32 Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $1.0M, growing to $1.0M next year.
Have analysts been upgrading or downgrading QTTB lately?+
As of Jul, 5 of 5 firms rate QTTB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their QTTB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
